Evidence map›Paper›PMID 20729863›Full record

ArticleNature structural & molecular biology2010

14-3-3 adaptor proteins recruit AID to 5'-AGCT-3'-rich switch regions for class switch recombination.

Zhenming Xu, Zsolt Fulop, Guikai Wu, Egest J Pone, Jinsong Zhang, Thach Mai, Lisa M Thomas, Ahmed Al-Qahtani, Clayton A White, Seok-Rae Park and 8 more

Open access · greenAbstract read
In one paragraph

Article in Nature structural & molecular biology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 131 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Epigenetics of the antibody and autoantibody response.Current opinion in immunology · 2020
    Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 2 countries.

Zhenming XuInstitute for Immunology, School of Medicine and School of Biological Sciences, University of California, Irvine, California, USA.
Zsolt Fulop
Guikai Wu
Egest J Pone
Jinsong Zhang
Thach Mai
Lisa M Thomas
Ahmed Al-Qahtani
Clayton A White
Seok-Rae Park
Petra Steinacker
Zenggang Li
John Yates
Bruce Herron
Markus Otto
Hong Zan
Haian Fu
Paolo Casali
University of California, Irvine · USEmory University · USUniversität Ulm · DENew York State Department of Health · USScripps Research Institute · US

Funding

ZDS2P REGULATES SWE1P-DEPENDENT POLARIZED CELL GROWTH IN S CEREVISIAEP41RR011823 · NCRR · UNIVERSITY OF WASHINGTON · PI DAVIS, TRACY · 1996 to 2011
$24.7M
TrainingP41GM103533 · NIGMS · UNIVERSITY OF WASHINGTON · PI MACCOSS, MICHAEL · 2012 to 2021
$20.7M
CARCINOGENESIST32CA009054 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI EDINGER, AIMEE L, FRUMAN, DAVID ALEXANDER · 1985 to 2025
$8.6M
Targeting Microtubules and HDAC6 in NSCLCP01CA116676 · NCI · EMORY UNIVERSITY · PI KHURI, FADLO RAJA · 2006 to 2012
$8.0M
Somatic hypermutation and class switching in autoimmunityR01AI079705 · NIAID · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI CASALI, PAOLO · 2010 to 2019
$4.1M
Immunoglobulin class switch DNA recombinationR01AI045011 · NIAID · WEILL MEDICAL COLLEGE OF CORNELL UNIV · PI CASALI, PAOLO · 2000 to 2011
$3.8M
Immunology Research Training ProgramT32AI060573 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI PEARLMAN, ERIC · 2005 to 2020
$1.9M
SOMATIC HYPERMUTATION IN HUMAN B CELLSR01AR040908 · NIAMS · WEILL MEDICAL COLLEGE OF CORNELL UNIV · PI CASALI, PAOLO · 1992 to 2005
$1.8M
Immunoglobulin class switch DNA recombinationR56AI045011 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI CASALI, PAOLO · 2012 to 2012
$523k
Molecular mechanisms in the generation of autoantibodies and lupusR56AI079705 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI CASALI, PAOLO · 2008 to 2008
$381k
NCI NIH HHS P01 CA 116676NCI NIH HHS P01 CA116676NCI NIH HHS T32 CA009054NCRR NIH HHS P41 RR011823NIAID NIH HHS AI 045011NIAID NIH HHS AI 060573NIAID NIH HHS AI 079705NIAID NIH HHS R01 AI045011NIAID NIH HHS R01 AI079705NIAID NIH HHS R56 AI045011NIAID NIH HHS R56 AI079705NIAID NIH HHS T32 AI060573NIAMS NIH HHS R01 AR040908NIGMS NIH HHS P41 GM103533
6 · The paper itself

Abstract

Class switch DNA recombination (CSR) is the mechanism that diversifies the biological effector functions of antibodies. Activation-induced cytidine deaminase (AID), a key protein in CSR, targets immunoglobulin H (IgH) switch regions, which contain 5'-AGCT-3' repeats in their core. How AID is recruited to switch regions remains unclear. Here we show that 14-3-3 adaptor proteins have an important role in CSR. 14-3-3 proteins specifically bound 5'-AGCT-3' repeats, were upregulated in B cells undergoing CSR and were recruited with AID to the switch regions that are involved in CSR events (Smu-->Sgamma1, Smu-->Sgamma3 or Smu-->Salpha). Moreover, blocking 14-3-3 by difopein, 14-3-3gamma deficiency or expression of a dominant-negative 14-3-3sigma mutant impaired recruitment of AID to switch regions and decreased CSR. Finally, 14-3-3 proteins interacted directly with AID and enhanced AID-mediated in vitro DNA deamination, further emphasizing the important role of these adaptors in CSR.

Indexed as

Immunoglobulin Switch RegionRecombination, Genetic14-3-3 ProteinsAICDA (Activation-Induced Cytidine Deaminase)AnimalsBase SequenceB-LymphocytesCell LineCytidine DeaminaseHumansMiceProtein Binding14-3-3 ProteinsAICDA (Activation-Induced Cytidine Deaminase)Cytidine Deaminase

Identifiers

PMID20729863
PMCPMC3645988
OpenAlexW1537884354

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.